HighTower Advisors
BEAM icon

HighTower Advisors’s Beam Therapeutics BEAM Stock Holding History

HighTower Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$319K Sell
9,289
-799
-8% -$24.1K ﹤0.01% 3164
2026
Q1 		$240K Sell
10,088
-316
-3% -$8.77K ﹤0.01% 3350
2025
Q4 		$288K Sell
10,404
-32
-0.3% -$816 ﹤0.01% 3077
2025
Q3 		$253K Buy
+10,436
New +$208K ﹤0.01% 3183
2022
Q2 		– Sell
-4,352
Closed -$251K – 3253
2022
Q1 		$251K Buy
4,352
+576
+15% +$37.8K ﹤0.01% 2658
2021
Q4 		$301K Buy
+3,776
New +$323K ﹤0.01% 2469

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

HighTower Advisors's BEAM Position: Q2 2026 in Review

HighTower Advisors reduced its Beam Therapeutics (BEAM) stake by 7.9% in Q2 2026, selling an estimated $24.1K and leaving 9,289 shares worth $319K. The position accounts for ﹤0.01% of the portfolio, ranked #3164.

HighTower Advisors first reported a position in BEAM in Q4 2021 and has held it in 6 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • HighTower Advisors held 9,289 shares of Beam Therapeutics worth $319K as of Q2 2026.
  • HighTower Advisors sold 799 Beam Therapeutics shares in Q2 2026, an estimated $24.1K.
  • Beam Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3164 holding.
  • HighTower Advisors first reported a position in Beam Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.